Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Core Insights - Trinity Biotech plc has secured an additional $4 million in debt financing from Perceptive Advisors to support its growth initiatives [1][2] - The funding will primarily aid the development of the company's continuous glucose monitoring (CGM) technology and its comprehensive transformation plan aimed at enhancing profitability and cash flow [2][3] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for both point-of-care and clinical laboratory segments, with a recent entry into the wearable biosensor market through the acquisition of Waveform Technologies Inc. [6] Financial Strategy - The comprehensive transformation plan is designed to increase operational efficiencies and financial strength across the company's portfolio [3] - The company is actively reviewing and managing the optimization of its business portfolio and capital structure to enhance profitability [3]